Compare Organon & Co. Common Stock (OGN) vs The Travelers Companies Inc. Common Stock (TRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs The Travelers Companies Inc. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while The Travelers Companies Inc. Common Stock trades at $377.77 (market cap $77.86B). The key difference: The Travelers Companies Inc. Common Stock is far larger — about 21.5× Organon & Co. Common Stock's market cap, and The Travelers Companies Inc. Common Stock pays the higher dividend (1.34%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and The Travelers Companies Inc. Common Stock for 6 Days on average.
| OGN | TRV | |
|---|---|---|
Market Cap | $3.62B | $77.86B |
Volume | 2,892,999 | 986,776 |
Sector | Health | Financials |
52-Week High | $13.81 | $397.22 |
52-Week Low | $5.70 | $261.57 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $86.44B |
Dividend Yield | 0.58% | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TRV trades at $373.28, up 0.43% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.03 and ROE of 26.32%, while consistently beating earnings estimates in recent quarters. Recent news highlights Travelers' earnings momentum ahead of Q3 results.
The outlook remains positive given valuation attractiveness and earnings beat history, though risks include competitive pressures and potential earnings volatility. Analyst consensus is mixed with 25% buy ratings but a $353.80 price target below current levels, suggesting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About The Travelers Companies Inc. Common Stock
The Travelers Companies provides property and casualty insurance for individuals, businesses, and organizations. Its products include auto, home, and commercial coverage.
Read more on TRV →
